Extended Data Fig. 6: Effects of TLR4 inhibitor TAK-242 on tumor-infiltrating immune cells.
From: Gut microbiota-derived hexa-acylated lipopolysaccharides enhance cancer immunotherapy responses
MC38 colorectal adenocarcinoma cells were subcutaneously implanted into PMB pre-treated or untreated mice. Measurements were taken at indicated time points post implantation. Anti-PD-1 was administered i.p. starting at day 10 after tumor implantation, and the TLR4 inhibitor TAK-242 was administered i.p. during anti-PD-1 therapy. Flow cytometry measurements of indicated immune cells isolated from tumors of treated mice are shown. Data shown were pooled from 2 experimental repeats with n = 10 mice per group (exact p-values provided in Source Data Extended Data Figures). No differences were statistically significant by Kruskal-Wallis test.
